Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Avaliação da disfunção imune na sepse

21 de setembro de 2026 atualizado por: University of Minnesota

Sepsis leads to sustained immune system dysfunction resulting in increased susceptibility to secondary infection while in the hospital or after discharge. Consequently, many of the ~2 million Americans that develop sepsis every year will end up back in the ICU, weeks and months later. The objective of this study is to define the cellular and molecular mechanisms driving the dysfunction and reprogramming of T cells and B cells that mediate cellular and humoral immunity using a combination of phenotypic, functional, genomic, and metabolomic assays.

Visão geral do estudo

Status

Recrutamento

Condições

Intervenção / Tratamento

Tipo de estudo

Observacional

Inscrição (Estimado)

150

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

  • Nome: Mrunmayi Tilak
  • Número de telefone: 612-624-9990
  • E-mail: mtilak@umn.edu

Locais de estudo

    • Minnesota
      • Minneapolis, Minnesota, Estados Unidos, 55455
        • Recrutamento
        • University of Minnesota
        • Contato:

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos e mais velhos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Sim

Gêneros Elegíveis para o Estudo

Tudo

Método de amostragem

Amostra Não Probabilística

População do estudo

Patients with and without sepsis in the ICU, compared to healthy volunteers

Descrição

ICU With Sepsis Inclusion Criteria:

  • Age ≥ 18

  • Presumed diagnosis of sepsis, defined as "patients with life-threatening organ dysfunction caused by a dysregulated host response to infection"

  • Patients in the ICU who meet 2 or more of the quick SOFA (qSOFA) definition along with organ dysfunction:

    1. Respiration rate ≥ 22 breaths/min and/or mechanically ventilated
    2. An alteration in mental status
    3. Systolic blood pressure of less than 100 mm Hg and/or receiving inotropes to maintain blood pressure AND/OR
    1. An acute change in SOFA score ≥2 points, consequent to the infection (can assume SOFA score = 0 in patients with no pre-existing organ dysfunction)

ICU Without Sepsis Inclusion Criteria:

  • Age ≥ 18
  • Patients requiring care at a M Health Fairview ICU due to high acuity of illness and no other evidence of sepsis

Healthy Volunteer Inclusion Criteria

  • Age greater or equal to 18
  • ASA status 1, 2 or 3
  • May include patients who are receiving dialysis in an outpatient setting

Exclusion Criteria (all groups):

  • Active cancer with chemotherapy and/or radiation treatment within the past 6 weeks
  • Medication usage that includes immunosuppressive drugs, biologic agents, cytokines, growth factor and interleukins
  • Steroid medication usage of > 300mg hydrocortisone per day (equivalent of > 20mg prednisone). Patients with chronic steroid use will be excluded, however patients who have had stress dose steroids administered following admission will be included.
  • Patients with a history of, or who currently have evidence of autoimmune disease, including but not limited to: myasthenia gravis, Guillain Barré syndrome, systemic lupus erythematosus, multiple sclerosis, scleroderma, ulcerative colitis, Crohn's disease, autoimmune hepatitis, Wegener's granulomatosis, HIV/AIDS, etc.
  • Patients with active or a history of acute or chronic lymphocytic leukemia
  • Known history of chronic hepatitis B (HBV) infection and not on treatment with HBV nucleoside analogues prior to the current hospitalization, or HBV DNA > 100 IU/mL
  • Known history of infection with hepatitis C (HCV) and currently undergoing treatment for HCV infection or has detectable HCV RNA
  • Participation in another investigational interventional drug study within the past 4 weeks
  • Current pregnancy
  • Current incarceration

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Modelos de observação: CASE_CONTROL
  • Perspectivas de Tempo: PROSPECTIVE

Coortes e Intervenções

Grupo / Coorte
Intervenção / Tratamento
Voluntários Saudáveis

No intervention is included in this study

Pacientes de UTI com sepse

No intervention is included in this study

Pacientes de UTI sem sepse

No intervention is included in this study

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
EliSpot - Day 1
Prazo: Day 1

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 1
EliSpot - Day 4
Prazo: Day 4

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 4
EliSpot - Day 7
Prazo: Day 7

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 7
EliSpot - Day 14
Prazo: Day 14

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 14
EliSpot - Day 21
Prazo: Day 21

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 21
EliSpot - Day 28
Prazo: Day 28

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 28
Ex Vivo TNF Production - Day 1
Prazo: Day 1

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 1
Ex Vivo TNF Production - Day 4
Prazo: Day 4

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 4
Ex Vivo TNF Production - Day 7
Prazo: Day 7

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 7
Ex Vivo TNF Production - Day 14
Prazo: Day 14

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 14
Ex Vivo TNF Production - Day 21
Prazo: Day 21

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 21
Ex Vivo TNF Production - Day 28
Prazo: Day 28

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 28
Flow Cytometry of Peripheral Blood Leukocytes - Day 1
Prazo: Day 1

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 1
Flow Cytometry of Peripheral Blood Leukocytes - Day 4
Prazo: Day 4

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 4
Flow Cytometry of Peripheral Blood Leukocytes - Day 7
Prazo: Day 7

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 7
Flow Cytometry of Peripheral Blood Leukocytes - Day 14
Prazo: Day 14

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 14
Flow Cytometry of Peripheral Blood Leukocytes - Day 21
Prazo: Day 21

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 21
Flow Cytometry of Peripheral Blood Leukocytes - Day 28
Prazo: Day 28

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 28
Quantification of Cytokines in Serum - Day 1
Prazo: Day 1

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 1
Quantification of Cytokines in Serum - Day 4
Prazo: Day 4

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 4
Quantification of Cytokines in Serum - Day 7
Prazo: Day 7

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 7
Quantification of Cytokines in Serum - Day 14
Prazo: Day 14

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 14
Quantification of Cytokines in Serum - Day 21
Prazo: Day 21

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 21
Quantification of Cytokines in Serum - Day 28
Prazo: Day 28

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 28
Quantification of Chemokines in Serum - Day 1
Prazo: Day 1

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 1
Quantification of Chemokines in Serum - Day 4
Prazo: Day 4

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 4
Quantification of Chemokines in Serum - Day 7
Prazo: Day 7

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 7
Quantification of Chemokines in Serum - Day 14
Prazo: Day 14

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 14
Quantification of Chemokines in Serum - Day 21
Prazo: Day 21

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 21
Quantification of Chemokines in Serum - Day 28
Prazo: Day 28

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 28
Transcriptional Profiling - Day 1
Prazo: Day 1

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 1
Transcriptional Profiling - Day 4
Prazo: Day 4

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 4
Transcriptional Profiling - Day 7
Prazo: Day 7

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 7
Transcriptional Profiling - Day 14
Prazo: Day 14

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 14
Transcriptional Profiling - Day 21
Prazo: Day 21

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 21
Transcriptional Profiling - Day 28
Prazo: Day 28

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 28
CBC - Day 1
Prazo: Day 1

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 1
CBC - Day 4
Prazo: Day 4

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 4
CBC - Day 7
Prazo: Day 7

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 7
CBC - Day 14
Prazo: Day 14

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 14
CBC - Day 21
Prazo: Day 21

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 21
CBC - Day 28
Prazo: Day 28

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 28

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Investigadores

  • Investigador principal: Thomas Griffith, PhD, University of Minnesota

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

1 de março de 2026

Conclusão Primária (Estimado)

1 de novembro de 2028

Conclusão do estudo (Estimado)

1 de novembro de 2028

Datas de inscrição no estudo

Enviado pela primeira vez

26 de agosto de 2025

Enviado pela primeira vez que atendeu aos critérios de CQ

26 de agosto de 2025

Primeira postagem (Real)

4 de setembro de 2025

Atualizações de registro de estudo

Última Atualização Postada (Real)

23 de setembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

21 de setembro de 2026

Última verificação

1 de setembro de 2026

Mais Informações

Termos relacionados a este estudo

Outros números de identificação do estudo

  • URO-2025-34202

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

NÃO

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever